Dr. Imperato is a PGY-3 emergency medicine resident and will be chief resident for this upcoming academic year at Rutgers New Jersey Medical School in Newark, NJ. He was a recipient of the NIDA CTN Mentor-Facilitated Training Award and was recently selected as a 2026 EMRA Health Policy Academy Fellow. His clinical interests include the management of toxicologic exposures and treatment of substance use disorders, with research interests in health policy and health insurance literacy.

Dr. Greller is an Associate Professor of Emergency Medicine, in the Department of Emergency Medicine, Division of Medical Toxicology and Addiction Medicine, at the Rutgers New Jersey Medical School. He is the director of the Medical Toxicology fellowship, and the co-director of the first combined fellowship in Addiction Medicine and Medical Toxicology. He is a passionate educator and researcher active in local, regional, and national efforts to confront our continued addiction crisis.

Dr. Meaden is director of Medical Toxicology Outpatient Services and an assistant professor of Emergency Medicine, Medical Toxicology & Addiction Medicine at Rutgers New Jersey Medical School.

References

1. Alcohol Use Disorder (AUD) in the United States: Age Groups and Demographic Characteristics | National Institute on Alcohol Abuse and Alcoholism (NIAAA). Accessed July 18, 2025. https://www.niaaa.nih.gov/alcohols-effects-health/alcohol-topics/alcohol-facts-and-statistics/alcohol-use-disorder-aud-united-states-age-groups-and-demographic-characteristics
2. Alcohol Use Disorder: A Comparison Between DSM–IV and DSM–5 | National Institute on Alcohol Abuse and Alcoholism (NIAAA). Accessed July 18, 2025. https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/alcohol-use-disorder-comparison-between-dsm
3. Drug Abuse Warning Network (DAWN) Short Report | Alcohol-related ED visits. https://www.samhsa.gov/data/sites/default/files/reports/rpt44498/DAWN-TargetReport-Alcohol-508.pdf
4. White AM, Slater ME, Ng G, Hingson R, Breslow R. Trends in Alcohol-Related Emergency Department Visits in the United States: Results from the Nationwide Emergency Department Sample, 2006 to 2014. Alcohol Clin Exp Res. 2018;42(2):352-359. doi:10.1111/acer.13559
5. Mintz CM, Hartz SM, Fisher SL, et al. A Cascade of Care for Alcohol Use Disorder: Using 2015–2019 National Survey on Drug Use and Health Data to Identify Gaps in Past 12-Month Care. Alcohol Clin Exp Res. 2021;45(6):1276-1286. doi:10.1111/acer.14609
6. Uong S, Tomedi LE, Gloppen KM, et al. Screening for Excessive Alcohol Consumption in Emergency Departments: A Nationwide Assessment of Emergency Department Physicians. J Public Health Manag Pract. 2022;28(1):E162-E169. doi:10.1097/PHH.0000000000001286
7. Cunningham RM, Harrison SR, McKay MP, et al. National survey of emergency department alcohol screening and intervention practices. Ann Emerg Med. 2010;55(6):556-562. doi:10.1016/j.annemergmed.2010.03.004
8. Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. Primary Care Validation of a Single-Question Alcohol Screening Test. J Gen Intern Med. 2009;24(7):783-788. doi:10.1007/s11606-009-0928-6
9. Bae SJ, Kim E, Lee JH. Validation of the screening test for at-risk drinking in an emergency department using a tablet computer. Drug Alcohol Depend. 2022;230:109181. doi:10.1016/j.drugalcdep.2021.109181
10. van Gils Y, Franck E, Dierckx E, van Alphen SPJ, Saunders JB, Dom G. Validation of the AUDIT and AUDIT-C for Hazardous Drinking in Community-Dwelling Older Adults. Int J Environ Res Public Health. 2021;18(17):9266. doi:10.3390/ijerph18179266
11. Cowan E, O’Brien-Lambert C, Eiting E, et al. Emergency department–initiated oral naltrexone for patients with moderate to severe alcohol use disorder: A pilot feasibility study. Academic Emergency Medicine. 2025;32(5). doi:10.1111/acem.15059
12. Borgundvaag B, Bellolio F, Miles I, et al. Guidelines for Reasonable and Appropriate Care in the Emergency Department (GRACE-4): Alcohol use disorder and cannabinoid hyperemesis syndrome management in the emergency department. Academic Emergency Medicine. 2024;31(5):425-455. doi:10.1111/acem.14911
13. Singh NM, Daniel K, Balasanova AA. Impact of hospital-administered extended-release naltrexone on readmission rates for patients with alcohol use disorder. Intern Med J. Published online July 10, 2024. doi:10.1111/imj.16467
14. Harlow TR, Peters JR, Anderson DL.. Successful Naloxone Challenge Test in a Patient With Atrial Flutter. Psychiatrist.com. Accessed July 31, 2025. https://www.psychiatrist.com/pcc/naloxone-challenge-test-in-patient-with-atrial-flutter/
15. Thompson R, Taddei T, Kaplan D, Rabiee A. Safety of naltrexone in patients with cirrhosis. JHEP Rep. 2024;6(7). doi:10.1016/j.jhepr.2024.101095
16. Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: When are these medications most helpful? Addiction. 2013;108(2):275-293. doi:10.1111/j.1360-0443.2012.04054.x
17. Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014;311(18):1889-1900. doi:10.1001/jama.2014.3628
18. Murphy CE, Coralic Z, Wang RC, Montoy JCC, Ramirez B, Raven MC. Extended-Release Naltrexone and Case Management for Treatment of Alcohol Use Disorder in the Emergency Department. Ann Emerg Med. 2023;81(4):440-449. doi:10.1016/j.annemergmed.2022.08.453
19. McPheeters M, O’Connor EA, Riley S, et al. Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis. JAMA. 2023;330(17):1653-1665. doi:10.1001/jama.2023.19761
20. Sharma AK, Rikhari P, Shukla AK, Rikhari P. Role of Acamprosate and Baclofen as Anti-craving Agents in Alcohol Use Disorder: A 12-Week Prospective Study. Cureus. 2024;16(4):e58174. doi:10.7759/cureus.58174
21. Yasaei R, Katta S, Patel P, Saadabadi A. Gabapentin. In: StatPearls. StatPearls Publishing; 2025. Accessed July 31, 2025. http://www.ncbi.nlm.nih.gov/books/NBK493228/
22. Kuehn BM. Gabapentin Increasingly Implicated in Overdose Deaths. JAMA. 2022;327(24):2387. doi:10.1001/jama.2022.10100
23. Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A. Gabapentin Treatment for Alcohol Dependence: A Randomized Controlled Trial. JAMA Intern Med. 2014;174(1):70-77. doi:10.1001/jamainternmed.2013.11950
24. Bahji A, Bach P, Danilewitz M, et al. Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis. J Addict Med. 2022;16(6):630-638. doi:10.1097/ADM.0000000000000992
25. Skinner MD, Lahmek P, Pham H, Aubin HJ. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS One. 2014;9(2):e87366. doi:10.1371/journal.pone.0087366
26. Krampe H, Ehrenreich H. Supervised disulfiram as adjunct to psychotherapy in alcoholism treatment. Curr Pharm Des. 2010;16(19):2076-2090. doi:10.2174/138161210791516431
27. Axelrath S. Disulfiram Should Remain Second-line Treatment for Most Patients With Alcohol Use Disorder. J Addict Med. 2024;18(6):617-618. doi:10.1097/ADM.0000000000001360
28. Chick J, Gough K, Falkowski W, et al. Disulfiram treatment of alcoholism. Br J Psychiatry. 1992;161:84-89. doi:10.1192/bjp.161.1.84
29. Burnette EM, Nieto SJ, Grodin EN, et al. Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder. Drugs. 2022;82(3):251-274. doi:10.1007/s40265-021-01670-3
30. Klausen MK, Thomsen M, Wortwein G, Fink‐Jensen A. The role of glucagon‐like peptide 1 (GLP‐1) in addictive disorders. Br J Pharmacol. 2022;179(4):625-641. doi:10.1111/bph.15677
31. Hendershot CS, Bremmer MP, Paladino MB, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025;82(4):395-405. doi:10.1001/jamapsychiatry.2024.4789
32. Lähteenvuo M, Tiihonen J, Solismaa A, Tanskanen A, Mittendorfer-Rutz E, Taipale H. Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder. JAMA Psychiatry. 2025;82(1):94-98. doi:10.1001/jamapsychiatry.2024.3599
33. Simpson TL, Achtmeyer C, Batten L, et al. Naltrexone augmented with prazosin for alcohol use disorder: results from a randomized controlled proof-of-concept trial. Alcohol Alcohol. 2024;59(5):agae062. doi:10.1093/alcalc/agae062
34. Rolland B. Baclofen approval in France: A balance between two conceptions of medicine. Eur Psychiatry. 2021;64(Suppl 1):S28. doi:10.1192/j.eurpsy.2021.101
35. Rose AK, Jones A. Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis. Addiction. 2018;113(8):1396-1406. doi:10.1111/add.14191
36. de Beaurepaire R, Jaury P. Baclofen in the treatment of alcohol use disorder: tailored doses matter. Alcohol Alcohol. 2024;59(2):agad090. doi:10.1093/alcalc/agad090
37. Phimarn W, Sakhancord R, Paitoon P, Saramunee K, Sungthong B. Efficacy of Varenicline in the Treatment of Alcohol Dependence: An Updated Meta-Analysis and Meta-Regression. Int J Environ Res Public Health. 2023;20(5):4091. doi:10.3390/ijerph20054091
38. Söderpalm B, Lidö H, Franck J, et al. Efficacy and safety of varenicline and bupropion, in combination and alone, for alcohol use disorder: a randomized, double-blind, placebo-controlled multicentre trial. The Lancet Regional Health – Europe. 2025;54. doi:10.1016/j.lanepe.2025.101310
39. Johnson B, Alho H, Addolorato G, et al. Low-dose ondansetron: A candidate prospective precision medicine to treat alcohol use disorder endophenotypes. European Journal of Internal Medicine. 2024;127:50-62. doi:10.1016/j.ejim.2024.06.001
40. Myrick H, Anton RF, Li X, Henderson S, Randall PK, Voronin K. Effect of Naltrexone and Ondansetron on Alcohol Cue–Induced Activation of the Ventral Striatum in Alcohol-Dependent People. Arch Gen Psychiatry. 2008;65(4):466-475. doi:10.1001/archpsyc.65.4.466
41. Squeglia LM, Tomko RL, Baker NL, Kirkland AE, McClure EA, Gray KM. A Randomized Controlled Trial of N-acetylcysteine for Adolescent and Young Adult Alcohol Use Disorder. JAACAP.2025;0(0). doi:10.1016/j.jaac.2025.09.025
42. Morley K, Arunogiri S, Connor JP, et al. N-acetyl cysteine for the treatment of alcohol use disorder: study protocol for a multi-site, double-blind randomised controlled trial (NAC-AUD study). Published online September 1, 2025. doi:10.1136/bmjopen-2024-091631
43. Haass-Koffler CL, Magill M, Cannella N, et al. Mifepristone as a pharmacological intervention for stress-induced alcohol craving: A human laboratory study. Addict Biol. 2023;28(7):e13288. doi:10.1111/adb.13288